Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure
Top Cited Papers
- 20 August 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Cell Metabolism
- Vol. 106 (8), 920-926
- https://doi.org/10.1161/01.cir.0000029801.86489.50
Abstract
Background— Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alone. Methods and Results— We randomly assigned 5770 patients with New York Heart Association class II to IV heart failure to double-blind treatment with either the ACE inhibitor enalapril (10 mg BID, n=2884) or to the ACE-NEP inhibitor omapatrilat (40 mg once daily, n=2886) for a mean of 14.5 months. The primary end point—the combined risk of death or hospitalization for heart failure requiring intravenous treatment—was used prospectively to test both a superiority and noninferiority hypothesis (based on the effect of enalapril in the Studies of Left Ventricular Dysfunction [SOLVD] Treatment Trial). A primary end point was achieved in 973 patients in the enalapril group and in 914 patients in the omapatrilat group (hazard ratio 0.94; 95% CI: 0.86 to 1.03, P=0.187)—a result that fulfilled prespecified criteria for noninferiority but n...Keywords
This publication has 13 references indexed in Scilit:
- Pharmacodynamics and Pharmacokinetics of Omapatrilat in Heart FailureThe Journal of Clinical Pharmacology, 2001
- Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trialThe Lancet, 2000
- Vasopeptidase Inhibition with Omapatrilat Improves Cardiac Geometry and Survival in Cardiomyopathic Hamsters More Than Does ACE Inhibition with CaptoprilJournal of Cardiovascular Pharmacology, 1999
- Pharmacodynamic effects of dual neutral endopeptidase–angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humansClinical Pharmacology & Therapeutics, 1999
- Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin‐1European Journal of Heart Failure, 1999
- Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibitionEuropean Heart Journal, 1998
- New Dual Inhibitors of Neutral Endopeptidase and Angiotensin-Converting Enzyme: Rational Design, Bioavailability, and Pharmacological Responses in Experimental HypertensionJournal of Medicinal Chemistry, 1994
- Plasma exudation in conscious dogs with experimental heart failureBasic Research in Cardiology, 1994
- Atrial natriuretic peptide in heart failureJournal of the American College of Cardiology, 1993
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991